Alnylam Pharmaceuticals, Inc., 10% Owner at Regulus Therapeutics Inc. ("RGLS"), sold 10,750 shares at $6.89 ($74K) on 2014-08-21, disclosed to the SEC on 2014-08-22.
Scheduled sale ($74k) by 10% Owner under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $7.14 | 3,000 | $21K | 28.9% |
| 2 | $6.89 | 2,500 | $17K | 23.3% |
| 3 | $6.75 | 5,250 | $35K | 47.8% |
| Total | $6.89 avg | 10,750 | $74K | 100% |
| Filing → |
| RGLS | SELL | 2014-10-24 | $1.6M | — | Filing → |
| RGLS | SELL | 2014-10-17 | $81K | — | Filing → |
| RGLS | SELL | 2014-10-10 | $66K | — | Filing → |